On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
AM Lesokhin, MK Callahan, MA Postow… - Science translational …, 2015 - science.org
AM Lesokhin, MK Callahan, MA Postow, JD Wolchok
Science translational medicine, 2015•science.orgThe recent approvals of two drugs that block the function of the immune checkpoint
programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the
mainstream of clinical oncology. We provide a historical and immunologic context for these
recent advances and discuss translational studies that provide insight into the efficacy of
cancer immunotherapy at the individual patient level.
programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the
mainstream of clinical oncology. We provide a historical and immunologic context for these
recent advances and discuss translational studies that provide insight into the efficacy of
cancer immunotherapy at the individual patient level.
The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level.
AAAS